

Supplementary table A: Survival from end of last chemotherapy cycle

<b>Survival analysis from end of chemotherapy</b>		<b>Total patients</b>	<b>Deaths</b>		<b>Hazard ratio (HR)</b>	<b>95% CI</b>		<b>Adjusted HR*</b>
		<b>N=7,866 (a)</b>	<b>n=7,149</b>	<b>%</b>				
<b>Time to treatment</b>	<b>&lt;18 days</b>	3,794	3,524	92.9	<b>1.00</b>			
	<b>≥18 days</b>	4,072	3,625	89.0	<b>0.84</b>	0.80	0.88	<b>0.88</b>
<b>Chemotherapy cycles</b>	<b>1-3 cycles</b>	2,413	2,300	95.3	<b>1.00</b>			
	<b>≥4 cycles</b>	5,453	4,849	88.9	<b>0.58</b>	0.55	0.60	<b>0.61</b>
<b>Radiotherapy</b>	<b>No chemo-radiotherapy</b>	7,095	6,538	92.1	<b>1.00</b>			
	<b>Chemo-radiotherapy</b>	771	611	79.2	<b>0.57</b>	0.53	0.62	<b>0.72</b>
<b>Trust first seen</b>	<b>Non-chemotherapy trust</b>	1,867	1,675	89.7	<b>1.00</b>			
	<b>Chemotherapy trust</b>	5,984	5,461	91.3	<b>1.05</b>	1.00	1.11	<b>1.04</b>
	<b>Missing / trust which saw &lt;20 cases</b>	15	13	86.7	<b>0.85</b>	0.49	1.47	<b>0.76</b>

(a) this excludes the 1,814 cases with chemotherapy only recorded in the NLCA and 902 who died before completing their final cycle of chemotherapy; HR hazard ratio; \*Adjusted for sex, age, performance status, co-morbidity index and stage

---

*95% CI*

---

*0.84 0.93*

*0.58 0.64*

*0.66 0.78*

*0.98 1.09*

*0.44 1.31*

---